In injectable veterinary euthanasia and short-duration anaesthesia, secobarbital sodium is processed as a sterile aqueous solution in which the ionized barbiturate is maintained within a narrow pH window of 9.0 to 10.5. Below 8.0 the free-acid fraction increases and precipitation occurs on vessel walls and filling nozzle surfaces; above 10.5 the ureide ring hydrolyzes at a rate that can reduce assay below 95.0% during refrigerated storage. A representative 50 mg/mL injection contains secobarbital sodium 50.0 g, benzyl alcohol 20.0 g, propylene glycol 350.0 g, and water for injection q.s. to 1000 mL; pH is adjusted with 1 N sodium hydroxide or hydrochloric acid under a nitrogen overlay. Multi-dose vial formulations require benzyl alcohol in the range of 1.5–2.0% v/v, while single-dose ampoules omit preservative and use a final vehicle osmolality adjusted with sodium chloride to 280–320 mOsm/kg. Published stability data for secobarbital sodium injection under terminal steam sterilization are limited; terminal autoclaving at 121°C for 15 minutes is therefore avoided because the sodium salt is susceptible to hydrolytic ring opening in alkaline solution. The preferred process is aseptic filtration through a 0.22 µm PVDF membrane validated by ASTM F838-20 into depyrogenated Type I glass vials per USP <660>.

Filling is conducted under unidirectional airflow with ISO 5 critical zone classification; filling nozzles are constructed of 316L stainless steel and silicone tubing is replaced after each lot. Peristaltic pumps with platinum-cured silicone tubing are used instead of rotary piston pumps to reduce particulate shedding into the alkaline vehicle. The release specification matrix includes sterility per USP <71>, particulate matter per USP <788>, pH per USP <791>, and bacterial endotoxin per USP <85>; the endotoxin limit is calculated from the maximum bolus dose and species body weight using the K/M formula. Batch reconciliation and cage storage must satisfy Schedule II controlled substance requirements under 21 CFR 1308.12, with distribution controlled through DEA Form 222 under 21 CFR 1305.17.

How Direct Compression Avoids Hydrolytic Degradation in 100 mg Veterinary Secobarbital Tablets

When direct compression is selected for oral tablets intended for canine and feline sedation protocols, the main process conflict is moisture-induced hydrolysis of the sodium salt during aqueous wet granulation. Secobarbital sodium is not wet-granulated with water unless the API has been formulated as an organic-solvent granulation or a dry blend; aqueous granulation liquid addition above 12% w/w introduces sufficient moisture to soften the barbiturate powder and reduce subsequent tablet content uniformity. A representative direct-compression formula for a 100 mg tablet contains secobarbital sodium 100 mg, microcrystalline cellulose 130 mg, lactose monohydrate 55 mg, crospovidone 12 mg, colloidal silicon dioxide 1.5 mg, and magnesium stearate 1.5 mg, giving a total tablet mass of 300 mg. The API ratio is 33.3% w/w, disintegrant 4.0% w/w, glidant 0.5% w/w, and lubricant 0.5% w/w. All powders are conditioned at 35–45% RH before weighing; the API is pre-sifted through a 60-mesh screen to reduce agglomerates. Batch records for low-dose barbiturate compression lines show content uniformity failures when the active particle size D90 exceeds 150 µm; milling to D90 75–90 µm is therefore required before blending.

Blending proceeds in a 200 L V-blender at 25 rpm for 10 minutes, followed by addition of magnesium stearate and mixing for 3 minutes. Compression is carried out on a 16-station rotary press with 8.0 mm round concave B tooling, main compression force 8–18 kN, and turret speed 20–40 rpm. Tablets are controlled to hardness 5–8 kp, friability ≤1.0% per USP <1216>, disintegration ≤15 minutes in 0.1 N HCl at 37°C, and dissolution per USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl with Q ≥75% at 45 minutes. The finished tablets are packaged in amber HDPE bottles with cotton and silica gel desiccant, sealed with child-resistant closures, and stored at 20–25°C. Because secobarbital is a Schedule II controlled substance, in-process weight reconciliation is performed after every compression run and all rejected tablets are segregated for destruction by a DEA-registered reverse distributor.

For feline and canine patients requiring patient-specific secobarbital doses that are not commercially available, capsule filling is performed as a nonsterile compounding operation under USP <795> rather than as a large-scale registered manufacturing line. A 50 mg secobarbital sodium capsule prepared in size 3 hard gelatin shells contains secobarbital sodium 50 mg, pregelatinized starch 90 mg, sodium starch glycolate 8 mg, colloidal silicon dioxide 1 mg, and magnesium stearate 1 mg; total fill weight is 150 mg. The API fraction is 33.3% w/w, disintegrant 5.3% w/w, and lubricant 0.7% w/w. Because this is a low-dose unit, geometric dilution is used before encapsulation: the secobarbital sodium is first triturated with an equal mass of pregelatinized starch, then successively diluted until the full batch size is reached. Batch sizes of 50–500 capsules are typical in veterinary compounding pharmacies; the operator works inside a ventilated balance enclosure with negative pressure and HEPA filtration to limit operator exposure to the controlled substance.

Encapsulation is performed on a semi-automatic capsule machine with a capacity of 1,000 capsules/hour. Relative humidity in the compounding area is held at 40–50% RH because hard gelatin shells become brittle below 35% RH and tacky above 55% RH; when hydroxypropyl methylcellulose shells are substituted for gelatin, the lower humidity limit is relaxed but the same general band is maintained. Content uniformity is evaluated by weighing each capsule and by analytical assay on 10 capsules per batch per USP <905>; the acceptance value is controlled at ≤15.0. Dissolution testing is performed using USP <711> Apparatus I at 100 rpm in 900 mL purified water with Q ≥75% at 45 minutes. A controlled-substance compounding log records the DEA Form 222 order number, API lot number, final capsule count, and waste destruction. Because the preservative and reconstitution requirements differ from the tablet form, the capsule is the preferred oral form for short-term anticonvulsant therapy when weight-adjusted dosing is required in cats and small dogs.

Alcohol-Based Fluid-Bed Granulation Endpoints for Secobarbital Oral Granules

For reconstitutable oral suspension granules used in equine or companion-animal medicine, secobarbital sodium is granulated as an intermediate because direct dispensing of free powder creates unacceptable weighing error in the field and exposes staff to airborne controlled substance. A representative 25% w/w secobarbital sodium granule contains 250 mg secobarbital sodium, lactose monohydrate 650 mg, povidone K30 40 mg, sodium starch glycolate 40 mg, and colloidal silicon dioxide 20 mg per 1,000 mg unit dose. The binder solution is prepared with povidone K30 dissolved in isopropyl alcohol 20% w/w; alcohol is selected because aqueous binder would promote hydrolysis and produce a sticky granule mass that cannot be screened. Granulation is carried out in a fluid-bed granulator with inlet air temperature 45°C, product temperature 28–32°C, inlet air dew point -20°C, and spray rate 20 g/min. The drying endpoint is reached when loss on drying is 1.5–2.5% w/w per USP <731>; the dried granule is milled through a 20-mesh screen and passed through a 500 µm sieve.

The granule is specified for particle size distribution with D10 75 µm, D50 180–250 µm, and D90 <500 µm to ensure adequate flow during sachet filling and rapid dispersion upon reconstitution with water. Finished granules are filled into unit-dose sachets of foil/paper/polyethylene laminate with moisture vapor transmission rate <0.05 g/m²/24 h; each sachet is labeled for reconstitution to 10 mg/mL by adding 25 mL purified water. The suspension is dispensed as an oral dose by graduated syringe, but the granule itself remains a dry intermediate until the point of dispensing. Compliance is governed by USP <795> for nonsterile compounding and by Schedule II controlled substance handling under 21 CFR 1308.12. Because secobarbital sodium is hygroscopic, the sachet filling line is maintained at <35% RH and 20–25°C; batch records document fill weight on 10 consecutive sachets and every sachet is destructively weighed after each fill cycle.

Veterinary compounding pharmacies that prepare customized secobarbital doses for non-food species dilute the controlled substance with lactose monohydrate or microcrystalline cellulose to form a 5% w/w or 10% w/w premix. A 10% w/w premix contains secobarbital sodium 10 g, lactose monohydrate 89 g, and colloidal silicon dioxide 1 g per 100 g; this dilution permits accurate weighing of low individual doses without requiring a microbalance during each patient encounter. The API is pre-sieved through an 80-mesh screen and the diluent is conditioned at 25°C and <35% RH before blending. Geometric dilution in a porcelain mortar is followed by blending in a 5 L cube blender at 25 rpm for 15 minutes. Aqueous granulation is not used in this premix because the sodium salt would absorb moisture and form a paste; dry blending preserves flowability and reduces hydrolysis.

The blended premix is packed into amber HDPE containers with desiccant and a child-resistant closure. Bulk density after blending is typically 0.45–0.65 g/mL; Carr index values of 25–35% indicate passable flow, but the operator is required to agitate the container before weighing because fine lactose monohydrate can stratify during storage. Environmental controls on the packaging line maintain 20–25°C and <35% RH. Compliance records include the API lot number, DEA Form 222 order number, compounded preparation record, final weight reconciliation, and a certificate of destruction for excess powder. Because this premix is an intermediate for further compounding, it is not labeled for direct administration; the final compounding record specifies the exact amount of premix required to deliver the prescribed secobarbital sodium dose. For food-producing species, residue depletion data are not established and use is limited to non-food animals under the extralabel use provisions of 21 CFR 530 and relevant state pharmacy regulations.

When a Preserved Oral Solution Is the Only Acceptable Dilution Form for Multi-Dose Veterinary Use

Aqueous oral solutions of secobarbital sodium are not stock items for multi-week storage because the sodium salt hydrolyzes in the presence of water at neutral to acidic pH. When a liquid form is required for small or debilitated patients, the product is compounded as a dry powder for reconstitution and assigned a short beyond-use date. A representative reconstitution vehicle contains purified water 100 mL, sodium benzoate 100 mg as preservative, sorbitol solution 20 mL, citric acid monohydrate 200 mg to adjust pH to 8.0–8.5, and saccharin sodium 50 mg. Secobarbital sodium is added to achieve 20 mg/mL; the pH is checked with a temperature-compensated electrode and adjusted with 1 N sodium hydroxide if needed. The vehicle is prepared under nitrogen sparge in a glass-lined vessel with an overhead propeller at 150 rpm for 20 minutes to ensure complete dissolution and to minimize oxidative discoloration.

The finished solution is filtered through a 10 µm polypropylene cartridge and filled into 100 mL amber Type III glass bottles with child-resistant dropper closures. Storage is at 2–8°C; beyond-use date is 14 days for an aqueous oral liquid containing a preservative, consistent with USP <795>. The solution is discarded if color changes from colorless to yellow or if particles appear. Because the preparation is a Schedule II controlled substance, the label must state the concentration, species, route, storage temperature, beyond-use date, and the statement that use is restricted to non-food animals. Vessel cleaning validation is performed after each batch because residual barbiturate on stainless steel surfaces is difficult to remove at pH below 9.0; a final rinse with 0.1 N sodium hydroxide is used before standard detergent washing.